The pediatric drugs market comprises drugs that are specially formulated for use in children. Pediatric drugs treat various ailments including infectious diseases, digestive diseases, respiratory diseases, and non-communicable diseases. Factors such as growth in childhood population, increase in pediatric healthcare expenditure, rise in lifestyle-related disorders, and technological advancements in pediatric drug delivery systems are aiding market growth. The pediatric formulations available are easier to swallow and have better taste profiles than regular drugs to encourage medication adherence among children.
The pediatric drugs market is estimated to be valued at USD 147.8 Bn in 2024 and is expected to reach USD 333 Bn by 2031, growing at a compound annual growth rate (CAGR) of 12.3% from 2024 to 2031.
Key Takeaways
Key players operating in the pediatric drugs market are Pfizer, GSK, Sanofi, Eli Lilly, and Merck & Co. These leading players are focusing on R&D and innovation to develop novel drugs and pediatric-friendly drug formulations including liquids, chewable tablets, and flavored suspensions.
The growing incidence of chronic and infectious diseases among children globally is fueling the demand for pediatric drugs. Furthermore, increasing healthcare accessibility and awareness about pediatric care in developing nations are supporting the expansion of the pediatric drugs market.
Market key trends
The pediatric drugs market is actively adopting digital transformation through technologies like 3D printing and artificial intelligence. 3D printing allows for personalized drug dosing and specialized drug formulations tailored to a child's needs. AI aids in pediatric drug discovery and clinical trial processing by analyzing huge medical datasets. It also facilitates precision medicine approaches for superior treatment outcomes. Another major Pediatric Drugs Market Trends is the shift towards pediatric drug combination therapies to treat multidimensional diseases effectively and reduce pill burden. This offers enhanced efficacy with minimal side effects.
Porter's Analysis
Threat of new entrants: The pediatric drug market requires high R&D investment and strict regulatory approvals which acts as a barrier for new companies.
Bargaining power of buyers: Individual buyers have low bargaining power but large healthcare organizations and hospitals have moderate bargaining power.
Bargaining power of suppliers: The suppliers of active pharmaceutical ingredients and contract manufacturing organizations have moderate bargaining power.
Threat of new substitutes: Alternate treatment options pose minimal threat being targeted for different ailments and age groups.
Competitive rivalry: The market is highly competitive with top companies engaging in new product launches and innovations.
Geographical regions
North America holds the major share of the global pediatric drugs market owing to the increasing healthcare expenditure and consumption of prescription drugs in the region.
Asia Pacific region is anticipated to witness the fastest growth during the forecast period due to growing economy, increasing healthcare spending and large patient pool of pediatric population in countries like India and China. Furthermore, low manufacturing costs in these regions attract international manufacturers to set up production sites.
Get this Report in Japanese Language: 小児用医薬品市場
Get this Report in Korean Language: 소아용약물시장
Author Bio:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
